InvestorsHub Logo
Followers 834
Posts 120153
Boards Moderated 17
Alias Born 09/05/2002

Re: guyschmid post# 963

Wednesday, 04/08/2015 8:51:25 AM

Wednesday, April 08, 2015 8:51:25 AM

Post# of 3039
Not only was the SVR4 rate 99%, but the trial also included prior null responders as well as treatment-naïve patients. Very bullish for the ABT-493/ABT-530 regimen, at least for GT1 patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News